Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals (Nasdaq: APLS) has announced the approval of equity awards for one new employee, effective October 1, 2024. These awards, granted outside the company's 2017 Stock Incentive Plan but under the 2020 Inducement Stock Incentive Plan, are in compliance with Nasdaq Listing Rule 5635(c)(4). The employee received 4,240 restricted stock units (RSUs). The vesting schedule for these RSUs is as follows:
- 25% of the shares will vest on the first anniversary of the grant date
- An additional 25% will vest annually thereafter
Vesting is subject to the employee's continued employment on each vesting date. These equity awards are considered material to the employee's acceptance of employment with Apellis Pharmaceuticals.
Apellis Pharmaceuticals (Nasdaq: APLS) ha annunciato l'approvazione di premi azionari per un nuovo dipendente, con effetto dal 1 ottobre 2024. Questi premi, concessi al di fuori del Piano di Incentivazione Azionaria del 2017 dell'azienda, ma sotto il Piano di Incentivazione Azionaria per Induzione del 2020, sono conformi alla Regola di Quotazione 5635(c)(4) della Nasdaq. Il dipendente ha ricevuto 4.240 unità di azioni vincolate (RSU). Il programma di maturazione per queste RSU è il seguente:
- Il 25% delle azioni maturerà il primo anniversario della data di concessione
- Un ulteriore 25% maturerà annualmente in seguito
La maturazione è soggetta alla continua occupazione del dipendente in ciascuna data di maturazione. Questi premi azionari sono considerati fondamentali per l'accettazione dell'impiego da parte del dipendente con Apellis Pharmaceuticals.
Apellis Pharmaceuticals (Nasdaq: APLS) ha anunciado la aprobación de premios de acciones para un nuevo empleado, con vigencia a partir del 1 de octubre de 2024. Estos premios, otorgados fuera del Plan de Incentivos Accionarios de 2017 de la empresa, pero bajo el Plan de Incentivos Accionarios de Inducción de 2020, cumplen con la Regla de Cotización 5635(c)(4) de Nasdaq. El empleado recibió 4,240 unidades de acciones restringidas (RSUs). El cronograma de adquisición de estas RSUs es el siguiente:
- El 25% de las acciones se adquirirán en el primer aniversario de la fecha de otorgamiento
- Un 25% adicional se adquirirá anualmente de ahí en adelante
La adquisición está sujeta a la continuación del empleo del empleado en cada fecha de adquisición. Estos premios de acciones son considerados materiales para la aceptación del empleo por parte del empleado con Apellis Pharmaceuticals.
Apellis Pharmaceuticals (Nasdaq: APLS)는 2024년 10월 1일부로 새로운 직원에 대한 주식 보상을 승인했다고 발표했습니다. 이 보상은 회사의 2017년 주식 인센티브 플랜 외부에서 제공되지만, 2020년 유도 주식 인센티브 플랜에 따라 주어지며, Nasdaq 상장 규칙 5635(c)(4)에 부합합니다. 이 직원은 4,240주의 제한 주식 유닛(RSU)을 받았습니다. 이 RSU의 베스팅 일정은 다음과 같습니다:
- 주식의 25%는 부여일의 첫 번째 기념일에 베스트 됩니다.
- 그 이후로 매년 추가로 25%가 베스트 됩니다.
베스팅은 각 베스팅 날짜에 직원의 지속적인 근무에 따라 달라집니다. 이러한 주식 보상은 Apellis Pharmaceuticals에서의 고용 수락에 중요하게 여겨집니다.
Apellis Pharmaceuticals (Nasdaq: APLS) a annoncé l'approbation de récompenses en actions pour un nouvel employé, avec effet à partir du 1er octobre 2024. Ces récompenses, accordées en dehors du Plan d'Incentive en Actions de 2017 de la société, mais dans le cadre du Plan d'Incentive en Actions d'Induction de 2020, sont conformes à la Règle de Cotation 5635(c)(4) du Nasdaq. L'employé a reçu 4 240 unités d'actions restreintes (RSUs). Le calendrier de vesting pour ces RSUs est le suivant :
- 25% des actions seront acquises au cours du premier anniversaire de la date d'octroi
- 25% supplémentaires seront acquis chaque année par la suite
L'acquisition dépend de la poursuite de l'emploi de l'employé à chacune des dates d'acquisition. Ces récompenses en actions sont considérées comme essentielles à l'acceptation de l'emploi par l'employé chez Apellis Pharmaceuticals.
Apellis Pharmaceuticals (Nasdaq: APLS) hat die Genehmigung von Aktienvergütungen für einen neuen Mitarbeiter bekannt gegeben, die ab dem 1. Oktober 2024 in Kraft treten. Diese Vergütungen werden außerhalb des Aktienoptionsplans von 2017 des Unternehmens gewährt, fallen jedoch unter den Induktions-Aktienoptionsplan von 2020 und entsprechen der Nasdaq-Listing-Regel 5635(c)(4). Der Mitarbeiter erhielt 4.240 beschränkte Aktieneinheiten (RSUs). Der Vesting-Zeitplan für diese RSUs ist wie folgt:
- 25 % der Aktien werden am ersten Jahrestag des Gewährungsdatums fällig
- Ein zusätzlicher 25 % wird danach jährlich fällig
Der Vesting ist an die Fortsetzung der Beschäftigung des Mitarbeiters an jedem Vesting-Datum gebunden. Diese Aktienvergütungen sind für die Akzeptanz der Beschäftigung des Mitarbeiters bei Apellis Pharmaceuticals von wesentlicher Bedeutung.
- Apellis Pharmaceuticals is attracting new talent with equity incentives
- The company is utilizing its 2020 Inducement Stock Incentive Plan to offer competitive compensation packages
- None.
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant date of October 1, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employee received 4,240 restricted stock units (RSUs). Each RSU will vest as to
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Apellis Forward-Looking Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding timing of anticipated regulatory submissions. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, as discussed in the “Risk Factors” section of Apellis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 21, 2023 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Media Contact:
Tracy Vineis
media@apellis.com
617.420.4839
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
How many restricted stock units (RSUs) did Apellis Pharmaceuticals (APLS) grant to the new employee?
What is the vesting schedule for the RSUs granted by Apellis Pharmaceuticals (APLS) on October 1, 2024?
Under which plan did Apellis Pharmaceuticals (APLS) grant the equity awards announced on October 4, 2024?
What Nasdaq rule did Apellis Pharmaceuticals (APLS) comply with for these equity awards?
